Financial Ratios HealthCare Global Enterprises Limited
Equities
HCG
INE075I01017
Healthcare Facilities & Services
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 555.30 INR | +2.50% |
|
-3.54% | -16.12% |
| Feb. 24 | Healthcare Global Enterprises rights issue up to 4.25 bln rupees approved | RE |
| Feb. 17 | Healthcare Global Enterprises approves equity shares issuance for 4.25 billion rupees | RE |
| Fiscal Period: March | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
Profitability | ||||||||||
Return on Assets | -0.97 | 2.34 | 3.74 | 3.87 | 3.56 | |||||
Return on Total Capital | -1.21 | 2.85 | 4.75 | 4.97 | 4.48 | |||||
Return On Equity % | -39 | 4.87 | 2.01 | 4.77 | 5.26 | |||||
Return on Common Equity | -35.88 | 6.86 | 3.39 | 5.71 | 5.08 | |||||
Margin Analysis | ||||||||||
Gross Profit Margin % | 52.04 | 53.8 | 54.28 | 54.78 | 53.58 | |||||
SG&A Margin | 1.87 | 1.96 | 2.64 | 3.24 | 3.29 | |||||
EBITDA Margin % | 6.48 | 12.76 | 14 | 13.97 | 14.08 | |||||
EBITA Margin % | -3.29 | 5.76 | 8.14 | 8.26 | 8.33 | |||||
EBIT Margin % | -3.29 | 5.69 | 8 | 8.13 | 8.01 | |||||
Income From Continuing Operations Margin % | -21.82 | 2.78 | 1.04 | 2.16 | 2.2 | |||||
Net Income Margin % | -19.09 | 3.84 | 1.73 | 2.52 | 2 | |||||
Net Avail. For Common Margin % | -19.09 | 3.84 | 1.73 | 2.52 | 2 | |||||
Normalized Net Income Margin | -5.62 | 0.78 | 2.37 | 2.42 | 1.4 | |||||
Levered Free Cash Flow Margin | -3.85 | 10.01 | 4.69 | 3.61 | -0.63 | |||||
Unlevered Free Cash Flow Margin | 3.16 | 13.73 | 8.03 | 6.81 | 3.43 | |||||
Asset Turnover | ||||||||||
Asset Turnover | 0.47 | 0.66 | 0.75 | 0.76 | 0.71 | |||||
Fixed Assets Turnover | 0.71 | 1.05 | 1.24 | 1.29 | 1.24 | |||||
Receivables Turnover (Average Receivables) | 5.01 | 6.32 | 6.24 | 6.4 | 6.38 | |||||
Inventory Turnover (Average Inventory) | 21.91 | 25.28 | 22.7 | 21.36 | 21.57 | |||||
Short Term Liquidity | ||||||||||
Current Ratio | 0.93 | 1.07 | 1.02 | 0.91 | 0.81 | |||||
Quick Ratio | 0.8 | 0.95 | 0.88 | 0.81 | 0.72 | |||||
Operating Cash Flow to Current Liabilities | 0.26 | 0.47 | 0.44 | 0.38 | 0.3 | |||||
Days Sales Outstanding (Average Receivables) | 72.88 | 57.8 | 58.53 | 57.22 | 57.18 | |||||
Days Outstanding Inventory (Average Inventory) | 16.66 | 14.44 | 16.08 | 17.14 | 16.92 | |||||
Average Days Payable Outstanding | 112.8 | 94.64 | 103.11 | 111.52 | 107.75 | |||||
Cash Conversion Cycle (Average Days) | -23.26 | -22.41 | -28.51 | -37.16 | -33.65 | |||||
Long Term Solvency | ||||||||||
Total Debt/Equity | 136.96 | 103.5 | 103.66 | 147.3 | 185.57 | |||||
Total Debt / Total Capital | 57.8 | 50.86 | 50.9 | 59.56 | 64.98 | |||||
LT Debt/Equity | 114.21 | 93.78 | 93.72 | 120.69 | 139.35 | |||||
Long-Term Debt / Total Capital | 48.2 | 46.08 | 46.02 | 48.8 | 48.8 | |||||
Total Liabilities / Total Assets | 64.92 | 60.18 | 62.46 | 68.05 | 72.06 | |||||
EBIT / Interest Expense | -0.29 | 0.96 | 1.5 | 1.59 | 1.23 | |||||
EBITDA / Interest Expense | 1 | 2.73 | 3.2 | 3.31 | 2.66 | |||||
(EBITDA - Capex) / Interest Expense | 0.69 | 1.87 | 1.73 | 1.42 | 1.21 | |||||
Total Debt / EBITDA | 8.59 | 4.03 | 3.11 | 3.93 | 4.79 | |||||
Net Debt / EBITDA | 7.14 | 3.13 | 2.43 | 2.99 | 3.88 | |||||
Total Debt / (EBITDA - Capex) | 12.47 | 5.88 | 5.75 | 9.18 | 10.51 | |||||
Net Debt / (EBITDA - Capex) | 10.36 | 4.56 | 4.5 | 6.99 | 8.52 | |||||
Growth Over Prior Year | ||||||||||
Total Revenues, 1 Yr. Growth % | -7.5 | 37.93 | 21.22 | 12.85 | 16.25 | |||||
Gross Profit, 1 Yr. Growth % | -13.83 | 42.6 | 22.3 | 13.89 | 13.69 | |||||
EBITDA, 1 Yr. Growth % | -45.73 | 171.88 | 32.97 | 12.6 | 17.15 | |||||
EBITA, 1 Yr. Growth % | -241.37 | -341.36 | 71.17 | 14.53 | 17.23 | |||||
EBIT, 1 Yr. Growth % | -245.44 | -338.35 | 70.37 | 14.73 | 14.45 | |||||
Earnings From Cont. Operations, 1 Yr. Growth % | 76.24 | -117.6 | -54.71 | 134.45 | 18.14 | |||||
Net Income, 1 Yr. Growth % | 81.32 | -127.77 | -45.38 | 64.08 | -7.78 | |||||
Normalized Net Income, 1 Yr. Growth % | 1.83 | -119.08 | 270.12 | 14.92 | -32.65 | |||||
Diluted EPS Before Extra, 1 Yr. Growth % | 41.27 | -123.32 | -47.1 | 63.33 | -8.45 | |||||
Accounts Receivable, 1 Yr. Growth % | 0.28 | 18.89 | 26.09 | -2.8 | 36.35 | |||||
Inventory, 1 Yr. Growth % | -9.24 | 41.99 | 27.74 | 11.45 | 24.27 | |||||
Net Property, Plant and Equip., 1 Yr. Growth % | -16.52 | 4.88 | 0.99 | 15.84 | 25.13 | |||||
Total Assets, 1 Yr. Growth % | -9.66 | 9.03 | 4.35 | 16.9 | 30.87 | |||||
Tangible Book Value, 1 Yr. Growth % | 141.49 | 13.79 | 0.21 | -13.27 | -22.58 | |||||
Common Equity, 1 Yr. Growth % | 82.86 | 24.83 | -1.12 | -4.04 | 11.71 | |||||
Cash From Operations, 1 Yr. Growth % | -7.39 | 82.64 | 14.3 | 13.11 | 11.43 | |||||
Capital Expenditures, 1 Yr. Growth % | -67.14 | 101.08 | 87.05 | 39.36 | 12.49 | |||||
Levered Free Cash Flow, 1 Yr. Growth % | -71.7 | -458.89 | -43.22 | -13.26 | -120.2 | |||||
Unlevered Free Cash Flow, 1 Yr. Growth % | -152.83 | 499.08 | -29.13 | -4.31 | -41.41 | |||||
Compound Annual Growth Rate Over Two Years | ||||||||||
Total Revenues, 2 Yr. CAGR % | 1.76 | 12.95 | 29.31 | 16.96 | 14.54 | |||||
Gross Profit, 2 Yr. CAGR % | -4.22 | 10.85 | 32.06 | 18.02 | 13.79 | |||||
EBITDA, 2 Yr. CAGR % | -26.49 | 21.47 | 90.14 | 22.36 | 14.85 | |||||
EBITA, 2 Yr. CAGR % | -8.46 | 84.72 | 103.26 | 40.02 | 15.87 | |||||
EBIT, 2 Yr. CAGR % | -8.21 | 86.19 | 101.51 | 39.81 | 14.59 | |||||
Earnings From Cont. Operations, 2 Yr. CAGR % | 167.6 | -44.3 | -71.76 | 3.05 | 66.43 | |||||
Net Income, 2 Yr. CAGR % | 179.32 | -29.03 | -61.05 | -5.33 | 23.01 | |||||
Normalized Net Income, 2 Yr. CAGR % | 95.04 | -55.93 | -15.98 | 106.24 | -12.03 | |||||
Diluted EPS Before Extra, 2 Yr. CAGR % | 145.66 | -42.6 | -64.88 | -7.05 | 22.28 | |||||
Accounts Receivable, 2 Yr. CAGR % | 8.05 | 9.19 | 22.44 | 10.7 | 15.12 | |||||
Inventory, 2 Yr. CAGR % | -11.21 | 13.52 | 34.68 | 19.31 | 17.68 | |||||
Net Property, Plant and Equip., 2 Yr. CAGR % | 13.54 | -6.43 | 2.92 | 8.16 | 20.4 | |||||
Total Assets, 2 Yr. CAGR % | 10.95 | -0.75 | 6.67 | 10.45 | 23.69 | |||||
Tangible Book Value, 2 Yr. CAGR % | 27.22 | 65.76 | 6.78 | -6.77 | -18.06 | |||||
Common Equity, 2 Yr. CAGR % | 20.94 | 51.09 | 11.1 | -2.59 | 3.54 | |||||
Cash From Operations, 2 Yr. CAGR % | 10.61 | 30.06 | 44.48 | 13.7 | 12.27 | |||||
Capital Expenditures, 2 Yr. CAGR % | -56.68 | -18.72 | 93.94 | 61.45 | 25.21 | |||||
Levered Free Cash Flow, 2 Yr. CAGR % | 52.72 | 0.79 | 42.75 | -29.82 | -58.14 | |||||
Unlevered Free Cash Flow, 2 Yr. CAGR % | 46.98 | 77.9 | 106.05 | -17.65 | -25.12 | |||||
Compound Annual Growth Rate Over Three Years | ||||||||||
Total Revenues, 3 Yr. CAGR % | 6.85 | 12.62 | 15.64 | 23.57 | 16.72 | |||||
Gross Profit, 3 Yr. CAGR % | 2.99 | 9.37 | 14.54 | 25.7 | 16.56 | |||||
EBITDA, 3 Yr. CAGR % | -17.34 | 13.68 | 25.19 | 59.67 | 20.6 | |||||
EBITA, 3 Yr. CAGR % | -10.89 | 26.46 | 80.09 | 67.88 | 31.97 | |||||
EBIT, 3 Yr. CAGR % | -10.75 | 26.17 | 80.76 | 67.02 | 30.79 | |||||
Earnings From Cont. Operations, 3 Yr. CAGR % | 135.46 | 8.03 | -48.01 | -42.82 | 7.85 | |||||
Net Income, 3 Yr. CAGR % | 111.24 | 29.4 | -34.96 | -37.1 | -6.15 | |||||
Normalized Net Income, 3 Yr. CAGR % | 67.18 | -10.14 | -10.42 | -6.73 | 42.02 | |||||
Diluted EPS Before Extra, 3 Yr. CAGR % | 92.67 | 12.07 | -44.14 | -41.37 | -7.52 | |||||
Accounts Receivable, 3 Yr. CAGR % | 12.66 | 11.55 | 14.56 | 13.37 | 18.66 | |||||
Inventory, 3 Yr. CAGR % | -4.22 | 3.84 | 18.07 | 26.44 | 20.94 | |||||
Net Property, Plant and Equip., 3 Yr. CAGR % | 13.45 | 10.58 | -4.02 | 7.06 | 13.55 | |||||
Total Assets, 3 Yr. CAGR % | 12.14 | 10.31 | 0.92 | 9.97 | 16.87 | |||||
Tangible Book Value, 3 Yr. CAGR % | 13.15 | 22.57 | 40.16 | -0.37 | -12.37 | |||||
Common Equity, 3 Yr. CAGR % | 10.62 | 22.22 | 31.17 | 5.81 | 1.96 | |||||
Cash From Operations, 3 Yr. CAGR % | 7.21 | 30.74 | 24.57 | 33.16 | 12.94 | |||||
Capital Expenditures, 3 Yr. CAGR % | -48.29 | -27.74 | 7.31 | 73.71 | 43.13 | |||||
Levered Free Cash Flow, 3 Yr. CAGR % | -42.68 | 103.04 | -16.76 | 20.91 | -53.66 | |||||
Unlevered Free Cash Flow, 3 Yr. CAGR % | -44.19 | 134.78 | 30.9 | 59.56 | -26.48 | |||||
Compound Annual Growth Rate Over Five Years | ||||||||||
Total Revenues, 5 Yr. CAGR % | 11.65 | 14.83 | 15.32 | 14.33 | 15.2 | |||||
Gross Profit, 5 Yr. CAGR % | 10.69 | 13.07 | 13.76 | 12.75 | 14.24 | |||||
EBITDA, 5 Yr. CAGR % | -4.77 | 11.39 | 15.35 | 17.08 | 20.95 | |||||
EBITA, 5 Yr. CAGR % | -3.88 | 10.97 | 23.93 | 31.72 | 50.97 | |||||
EBIT, 5 Yr. CAGR % | -3.88 | 10.69 | 23.62 | 31.46 | 50.63 | |||||
Earnings From Cont. Operations, 5 Yr. CAGR % | 150.56 | 11.05 | 0.8 | 6.01 | -17.2 | |||||
Net Income, 5 Yr. CAGR % | 165.7 | 19.37 | 7.42 | 14.2 | -16.08 | |||||
Normalized Net Income, 5 Yr. CAGR % | 174.35 | -11.03 | 26.96 | 25.28 | -11.06 | |||||
Diluted EPS Before Extra, 5 Yr. CAGR % | 47.46 | 8.1 | -2.47 | 3.99 | -23.58 | |||||
Accounts Receivable, 5 Yr. CAGR % | 20.11 | 15.94 | 16.47 | 11.21 | 14.78 | |||||
Inventory, 5 Yr. CAGR % | 9.6 | 9.81 | 9.77 | 9.77 | 17.92 | |||||
Net Property, Plant and Equip., 5 Yr. CAGR % | 15.12 | 12.15 | 9.12 | 9.61 | 5.09 | |||||
Total Assets, 5 Yr. CAGR % | 14.3 | 12.6 | 9.91 | 10.36 | 9.48 | |||||
Tangible Book Value, 5 Yr. CAGR % | 9.85 | 12.55 | 10.56 | 9.86 | 13.08 | |||||
Common Equity, 5 Yr. CAGR % | 10.36 | 15 | 10.81 | 11.62 | 19.33 | |||||
Cash From Operations, 5 Yr. CAGR % | 10.49 | 19.25 | 20.8 | 23.64 | 19.5 | |||||
Capital Expenditures, 5 Yr. CAGR % | -29.97 | -18.04 | -12.26 | -0.33 | 14.14 | |||||
Levered Free Cash Flow, 5 Yr. CAGR % | -11.88 | 16.85 | -17.43 | 32.75 | -36.77 | |||||
Unlevered Free Cash Flow, 5 Yr. CAGR % | -8.89 | 29.86 | -5.89 | 54.41 | 4.69 |
Select your edition
All financial news and data tailored to specific country editions
















